Gene Therapy Market Segmented On The Basis Of Indication, Vector Type, Region And Forecast To 2022 To 2030 Grand View Research Inc.

San Francisco, 9 Aug 2022: The Report Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 – 2028

The global gene therapy market size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures.

This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments.

Various universities and institutes are observed to exhibit a broad portfolio in the pipeline, which is anticipated to boost revenue generation in the future. The market is anticipated to witnesses a short-term revenue slowdown due to a shift in focus and delay in product launches. However, initiatives for developing novel trial designs, improving the regulatory environment, and managing the supply chain are expected to play a critical role in minimizing the impact of the current global crisis.

Access Research Report of Gene Therapy Market @ https://www.grandviewresearch.com/industry-analysis/gene-therapy-market

Gene Therapy Market Report Highlights

• Viral vectors have proven their efficiency as a method for effective gene deliveries. As a result, a substantial number of research communities and biotechnology companies have designed their gene therapy programs based on viral vectors
• Moreover, most of currently FDA-secured products involve the use of viral vectors, which contributes to the dominance of the viral vectors segment
• Due to the approval and huge success of lentivirus-based Kymriah and retrovirus-based Yescarta, retrovirus and lentivirus are also among the key revenue-generating segments
• Cancer has led the revenue flow in the market over the past few years and is expected to maintain its dominance in the forecast period
• The presence of approved products for various cancer forms including Large B-cell lymphoma, Acute Lymphoblastic Leukemia (ALL), and melanoma has resulted in the dominance of this segment
• The U.S. is recognized as the hub for clinical trials related to gene therapy. This has significantly impacted the revenue growth of the North America market
• Also, the success of Yescarta and Kymriah in the U.S. as the first approved CAR-t therapy programs has driven huge investments by various government agencies, sponsors, and key companies in this region
• Major market participants are partnering with other key stakeholders via signing licensing, commercialization, and development deals to enhance their worldwide business operations
• For instance, in June 2020, uniQure announced a license agreement with CSL Behring for the commercialization of hemophilia B gene therapy

List of Key Players of Gene Therapy Market

• REGENXBIO, Inc.
• Oxford BioMedica plc
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• SANOFI
• Applied Genetic Technologies Corporation
• Hoffmann-La Roche Ltd.
• Bluebird Bio, Inc.
• Novartis AG
• Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
• UniQure N.V.
• Shire Plc
• Cellectis S.A.
• Sangamo Therapeutics, Inc.
• Orchard Therapeutics
• Gilead Lifesciences, Inc.
• Benitec Biopharma Ltd.
• Sibiono GeneTech Co., Ltd.
• Shanghai Sunway Biotech Co., Ltd.
• Gensight Biologics S.A.
• Transgene
• Calimmune, Inc.
• Epeius Biotechnologies Corp.
• Astellas Pharma, Inc.
• American Gene Technologies
• BioMarin Pharmaceuticals, Inc.

Access Press Release of Gene Therapy Market @ https://www.grandviewresearch.com/press-release/global-gene-therapy-market

Gene Therapy Market Projected To Exhibit Robust CAGR of 20.4%For The Forecast Period From 2021 To 2028: Grand View Research Inc.

San Francisco, 29 April 2021: The Report Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 – 2028

The global gene therapy market size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures.

This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments.

Various universities and institutes are observed to exhibit a broad portfolio in the pipeline, which is anticipated to boost revenue generation in the future. The market is anticipated to witnesses a short-term revenue slowdown due to a shift in focus and delay in product launches. However, initiatives for developing novel trial designs, improving the regulatory environment, and managing the supply chain are expected to play a critical role in minimizing the impact of the current global crisis.

Access Research Report of Gene Therapy Market @ https://www.grandviewresearch.com/industry-analysis/gene-therapy-market

Gene Therapy Market Report Highlights

• Viral vectors have proven their efficiency as a method for effective gene deliveries. As a result, a substantial number of research communities and biotechnology companies have designed their gene therapy programs based on viral vectors
• Moreover, most of currently FDA-secured products involve the use of viral vectors, which contributes to the dominance of the viral vectors segment
• Due to the approval and huge success of lentivirus-based Kymriah and retrovirus-based Yescarta, retrovirus and lentivirus are also among the key revenue-generating segments
• Cancer has led the revenue flow in the market over the past few years and is expected to maintain its dominance in the forecast period
• The presence of approved products for various cancer forms including Large B-cell lymphoma, Acute Lymphoblastic Leukemia (ALL), and melanoma has resulted in the dominance of this segment
• The U.S. is recognized as the hub for clinical trials related to gene therapy. This has significantly impacted the revenue growth of the North America market
• Also, the success of Yescarta and Kymriah in the U.S. as the first approved CAR-t therapy programs has driven huge investments by various government agencies, sponsors, and key companies in this region
• Major market participants are partnering with other key stakeholders via signing licensing, commercialization, and development deals to enhance their worldwide business operations
• For instance, in June 2020, uniQure announced a license agreement with CSL Behring for the commercialization of hemophilia B gene therapy

List of Key Players of Gene Therapy Market

• REGENXBIO, Inc.
• Oxford BioMedica plc
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• SANOFI
• Applied Genetic Technologies Corporation
• Hoffmann-La Roche Ltd.
• Bluebird Bio, Inc.
• Novartis AG
• Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
• UniQure N.V.
• Shire Plc
• Cellectis S.A.
• Sangamo Therapeutics, Inc.
• Orchard Therapeutics
• Gilead Lifesciences, Inc.
• Benitec Biopharma Ltd.
• Sibiono GeneTech Co., Ltd.
• Shanghai Sunway Biotech Co., Ltd.
• Gensight Biologics S.A.
• Transgene
• Calimmune, Inc.
• Epeius Biotechnologies Corp.
• Astellas Pharma, Inc.
• American Gene Technologies
• BioMarin Pharmaceuticals, Inc.

Access Press Release of Gene Therapy Market @ https://www.grandviewresearch.com/press-release/global-gene-therapy-market

Gene Therapy Market is Predicted to Observe a Tremendous Growth, With a CAGR of 20.4% From 2021 To 2028: Grand View Research Inc.

San Francisco, 11 Feb 2021: The Report Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-cell Lymphoma, Beta-Thalassemia Major/SCD), By Vector Type (Lentivirus, AAV), By Region, And Segment Forecasts, 2021 – 2028

The global gene therapy market size is expected to reach USD 10.0 billion by 2028 registering a CAGR of 20.4% during the forecast period, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer coupled with the lack of effective treatment for the disease. Constant expansion of cancer genetic studies has deciphered relevant information about cancer-related molecular signatures.

This has driven the clinical trials for advanced cancer therapeutics, thereby driving the market growth. In addition, expansion of this mode of treatment in non-cancer applications with approval of therapies, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia and others, demonstrates the shift in the preferences of companies towards other unsaturated segments.

Various universities and institutes are observed to exhibit a broad portfolio in the pipeline, which is anticipated to boost revenue generation in the future. The market is anticipated to witnesses a short-term revenue slowdown due to a shift in focus and delay in product launches. However, initiatives for developing novel trial designs, improving the regulatory environment, and managing the supply chain are expected to play a critical role in minimizing the impact of the current global crisis.

Access Research Report of Gene Therapy Market @ https://www.grandviewresearch.com/industry-analysis/gene-therapy-market

Gene Therapy Market Report Highlights

• Viral vectors have proven their efficiency as a method for effective gene deliveries. As a result, a substantial number of research communities and biotechnology companies have designed their gene therapy programs based on viral vectors
• Moreover, most of currently FDA-secured products involve the use of viral vectors, which contributes to the dominance of the viral vectors segment
• Due to the approval and huge success of lentivirus-based Kymriah and retrovirus-based Yescarta, retrovirus and lentivirus are also among the key revenue-generating segments
• Cancer has led the revenue flow in the market over the past few years and is expected to maintain its dominance in the forecast period
• The presence of approved products for various cancer forms including Large B-cell lymphoma, Acute Lymphoblastic Leukemia (ALL), and melanoma has resulted in the dominance of this segment
• The U.S. is recognized as the hub for clinical trials related to gene therapy. This has significantly impacted the revenue growth of the North America market
• Also, the success of Yescarta and Kymriah in the U.S. as the first approved CAR-t therapy programs has driven huge investments by various government agencies, sponsors, and key companies in this region
• Major market participants are partnering with other key stakeholders via signing licensing, commercialization, and development deals to enhance their worldwide business operations
• For instance, in June 2020, uniQure announced a license agreement with CSL Behring for the commercialization of hemophilia B gene therapy

List of Key Players of Gene Therapy Market

• REGENXBIO, Inc.
• Oxford BioMedica plc
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• SANOFI
• Applied Genetic Technologies Corporation
• Hoffmann-La Roche Ltd.
• Bluebird Bio, Inc.
• Novartis AG
• Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
• UniQure N.V.
• Shire Plc
• Cellectis S.A.
• Sangamo Therapeutics, Inc.
• Orchard Therapeutics
• Gilead Lifesciences, Inc.
• Benitec Biopharma Ltd.
• Sibiono GeneTech Co., Ltd.
• Shanghai Sunway Biotech Co., Ltd.
• Gensight Biologics S.A.
• Transgene
• Calimmune, Inc.
• Epeius Biotechnologies Corp.
• Astellas Pharma, Inc.
• American Gene Technologies
• BioMarin Pharmaceuticals, Inc.

Access Press Release of Gene Therapy Market @ https://www.grandviewresearch.com/press-release/global-gene-therapy-market

Gene Therapy Market Projected To Expand At A CAGR 16.6% For The Forecast Period From 2020 To 2027: Grand View Research Inc.

San Francisco, 22 Dec 2020: The Report Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type, By Region, And Segment Forecasts, 2020 – 2027

The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period, according to a new report by Grand View Research, Inc. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth.

Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio’s Zynteglo in June 2019 for β-thalassemia, indicates the shift in preferences of companies toward other untapped segments.

Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space.

Access Research Report of Gene Therapy Market @ https://www.grandviewresearch.com/industry-analysis/gene-therapy-market

Further key findings from the study suggest:

• Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors
• In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA
• Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma
• North America dominated the global gene therapy market in 2019 as U.S. is the largest market for clinical trials related to gene therapy, since around 60.0% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America
• Key market players include Bluebird Bio, Novartis AG, UniQure NV, Gilead Sciences, Spark Therapeutics LLC, and Celgene Corporation
• These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics’ Luxturna for selling the product outside U.S.

Access Press Release of Gene Therapy Market @ https://www.grandviewresearch.com/press-release/global-gene-therapy-market

Gene Therapy Market Size Was Valued At USD 5.55 Billion By 2026: Grand View Research Inc.

San Francisco, 16 July 2019: The Report Gene Therapy Market Size, Share & Trends Analysis Report By Vector (Lentivirus, RetroVirus & Gamma RetroVirus), By Indication (Beta-Thalassemia Major/SCD, ALL, Large B-cell Lymphoma), And Segment Forecasts, 2019 – 2026

The global gene therapy market size is expected to reach USD 5.55 billion by 2026, growing at a CAGR of 33.9% over the forecast period, according to a new report by Grand View Research, Inc. Gene therapy is being developed with an aim to identify and cure rare conditions, diseases that have limited treatment options and that need lifelong medication to keep the symptoms in check. For instance, metabolic disorders like lysosomal diseases need constant medical attention with the medication available now, however, gene therapy might become a one-time cure to such diseases.

There are a number of molecules under development due to intense competition. This factor is projected to be the key factor propelling the market growth. In early 2018, there were more than 950 molecules in the pipeline with various regulatory bodies in various clinical phases. However, around 76% of the molecules are in the developmental or preclinical stages and are expected to be available by the late 2020s. Larger pharma/biotech companies are entering into the market by either acquiring the licensing/manufacturing rights from smaller companies that are solely dedicated to gene therapy research or by building a dedicated research portfolio with investments and clinical trials.

These factors are also expected to boost the market growth over the next two decades. Most of the manufacturers are also developing molecules that can help cure various cancers. Growing prevalence of different types of cancer emphasizes the need for the development of robust treatment options. Ongoing developments in cancer gene studies have provided significant information about cancer-related molecular signatures, which in turn, is expected to support the ongoing clinical trials for cancer therapeutics.

Access Research Report of Gene Therapy Market @ www.grandviewresearch.com/industry-analysis/gene-therapy-market

Further key findings from the study suggest:

• 7 gene therapy molecules have been approved by various regulatory bodies. In 2018, the FDA approved 3 molecules
• Lentivirus is being used as viral vector of choice for 2 of the 3 molecules approved by the FDA
• S. and Europe are expected to occupy the largest market shares over the forecast period owing to gene therapy molecules being marketed in these regions
• Europe is set to grow at a fast pace due to the growing pipeline molecules and a number of companies competing in the regional market
• Key companies in the market are Novartis AG, Gilead Sciences, Inc.; UniQure N.V.; Spark Therapeutics LLC; Bluebird Bio; Juno Therapeutics; GlaxoSmithKline PLC; Celgene Corporation; Shire PLC; Sangamo Biosciences, Inc.; Dimension Therapeutics, Inc.; Voyager Therapeutics, Inc.; Human Stem Cell Institute; Chiesi Farmaceutici S.p.A.; and Bristol-Myers Squibb Company

Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global gene therapy market on the basis of indication, vector, and region:

Gene Therapy Indication Outlook (Revenue, USD Million, 2014 – 2026)

• Acute Lymphoblastic Leukemia (ALL)
• Inherited Retinal Disease
• Large B-Cell Lymphoma
• ADA-SCID
• Melanoma (Lesions)
• Beta-Thalassemia Major/SCD
• Head & Neck Squamous Cell Carcinoma
• Peripheral Arterial Disease

Gene Therapy Vector Outlook (Revenue, USD Million, 2014 – 2026)

• Lentivirus
• Adeno-Associated Virus (AAV)
• RetroVirus & Gamma RetroVirus
• Modified Herpes Simplex Virus
• Adenovirus
• Vaccinia Virus
• Baculovirus (Bacmid)
• NON-VIRAL Plasmid Vector
• Injection of Naked DNA
• Lipofection

Gene Therapy Regional Outlook (Revenue, USD Million, 2014 – 2026)

• North America
• Europe
• Asia Pacific
• Rest of the World

Access Press Release of Gene Therapy Market @ www.grandviewresearch.com/press-release/global-gene-therapy-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com